Eisai Inc.'s sales force for the acid reflux therapy Aciphex in the U.S. gives Arena Pharmaceuticals Inc. just the oomph needed to push the obesity drug lorcaserin, due for an FDA panel hearing in September. San Diego-based Arena's stock (NASDAQ:ARNA) closed at $3.56, up 49 cents, or 16 percent, on news of the marketing deal disclosed Thursday. (BioWorld Today) Read More
